Alliances in Drug Discovery - The Chemical Element

02-Sep-2005

Alliances have evolved into a critical cornerstone of R&D strategy in the global pharmaceutical industry. No other industry has been leveraging this business model as successfully as the global pharmaceutical industry in its drive for innovation and success. Over three thousand deals amounting to a cumulative payout of US$ 17bn have been signed by pharmaceutical and biotech players in a span of two decades. In the past five years the industry's mania to develop new generation blockbuster drugs has taken on a new sense of urgency as 64% of the alliance value was inked and paid out during the period.

Frost & Sullivan is organizing a premium event, "Global PharmAlliance 2005 - Becoming the partner of choice" being held at Mumbai (India) on September 30th and 1st October, 2005. A gathering of experts and leaders from Indian and global Life Sciences industry, the conference will serve as a conclave of thought leaders and insights into their learning's and also serve as an ideal platform for networking and initiation of business partnerships. With international participation expected from leading pharmaceutical companies, contract service providers this summit could be an arena for knowledge exchange in the areas of R&D, strategic partnership and outsourcing, emerging technologies in drug manufacturing, custom synthesis, clinical research, marketing and distribution, global leadership, and many more. The two day event not only focuses on giving an insight into the world of partnerships and alliances through presentations and discussions but also recognizes the companies who have been the best at partnering through the Frost & Sullivan Awards - Partner of Choice.

https://www.bionity.com/en/news/48749/alliances-in-drug-discovery-the-chemical-element.html